BR112018068986A2 - composição para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, método para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, e método para produzir células ips - Google Patents

composição para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, método para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, e método para produzir células ips

Info

Publication number
BR112018068986A2
BR112018068986A2 BR112018068986A BR112018068986A BR112018068986A2 BR 112018068986 A2 BR112018068986 A2 BR 112018068986A2 BR 112018068986 A BR112018068986 A BR 112018068986A BR 112018068986 A BR112018068986 A BR 112018068986A BR 112018068986 A2 BR112018068986 A2 BR 112018068986A2
Authority
BR
Brazil
Prior art keywords
individual
tissue
expression
cell
composition
Prior art date
Application number
BR112018068986A
Other languages
English (en)
Other versions
BR112018068986B1 (pt
Inventor
Brian Reid Christopher
T Collins Que
Original Assignee
Brian Reid Christopher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brian Reid Christopher filed Critical Brian Reid Christopher
Publication of BR112018068986A2 publication Critical patent/BR112018068986A2/pt
Publication of BR112018068986B1 publication Critical patent/BR112018068986B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

o presente pedido trata de uma composição para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, a qual compreende pelo menos um óleo ou extrato selecionado a partir de um grupo que consiste em um óleo ou extrato de laranja, olíbano e cannabis. um modo para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, o qual compreende administrar, ao indivíduo, uma composição que compreende pelo menos um óleo ou extrato selecionado a partir do grupo que consiste em um óleo ou extrato de laranja, olíbano e cannabis.ipi
BR112018068986-6A 2016-03-18 2017-05-18 Composição para reduzir a expressão oncógena de uma célula, tecido ou órgão de um indivíduo BR112018068986B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662390081P 2016-03-18 2016-03-18
US62/390,081 2016-03-18
US201662390438P 2016-03-29 2016-03-29
US62/390,438 2016-03-29
PCT/US2017/033234 WO2017161387A1 (en) 2016-03-18 2017-05-18 Compositions of natural extracts and use thereof in methods for preventing or treating diseases

Publications (2)

Publication Number Publication Date
BR112018068986A2 true BR112018068986A2 (pt) 2019-01-22
BR112018068986B1 BR112018068986B1 (pt) 2023-03-21

Family

ID=59850464

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068986-6A BR112018068986B1 (pt) 2016-03-18 2017-05-18 Composição para reduzir a expressão oncógena de uma célula, tecido ou órgão de um indivíduo

Country Status (6)

Country Link
US (1) US20190224193A1 (pt)
BR (1) BR112018068986B1 (pt)
IL (1) IL261884B (pt)
MX (1) MX2018011348A (pt)
WO (1) WO2017161387A1 (pt)
ZA (1) ZA201806128B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6992057B2 (ja) 2016-06-10 2022-01-13 クラリティ コスメティックス インコーポレイテッド 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US11318179B2 (en) * 2017-06-20 2022-05-03 Jessica Kado Topical formulation for binding to dermatological cannabinoid receptors
PE20200731A1 (es) 2017-09-28 2020-07-23 Canopy Growth Corp Composiciones de cannabinoides comestibles
KR101959404B1 (ko) * 2017-11-09 2019-03-21 한국콜마주식회사 변색내성이 우수한 조합향료 함유 화장료 조성물
WO2019104291A1 (en) * 2017-11-27 2019-05-31 La'au Pono Combination of granulated dried botanical extract powder for symptom relief
AU2019232717A1 (en) * 2018-03-05 2020-09-24 Laila Nutraceuticals Synergistic herbal compositions for the treatment of obesity and overweight
CN108796065B (zh) * 2018-06-26 2020-08-04 青岛泱深生物医药有限公司 Fam127a在妊娠疾病中的应用
WO2020033796A1 (en) * 2018-08-10 2020-02-13 Metagenics, Inc. Method of treating inflammatory bowel disease
US20200103396A1 (en) * 2018-09-27 2020-04-02 T. Que COLLINS Deuterium depletion measurement
EP3870151A1 (en) * 2018-11-26 2021-09-01 Offhealth S.p.A. Collyrium containing citrus extract in liposomal form
EP3977132A1 (en) * 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2021030679A2 (en) * 2019-08-14 2021-02-18 University Of Louisville Research Foundation, Inc. Compositions and methods for diagnosis and treatment of metabolic diseases and disorders
CN111053761B (zh) * 2020-01-16 2022-05-03 杭州旦承医药科技有限公司 一种吸入用双膦酸类药物及其制备方法及其在慢性阻塞性肺疾病的用途
CN111514311B (zh) * 2020-04-15 2023-01-31 郑州大学第一附属医院 共载阿霉素和si-PVT1的靶向外泌体及其制备和抗骨肉瘤应用
CA3181178A1 (en) * 2020-05-06 2021-11-11 Regeneron Pharmaceuticals, Inc. Kelch domain containing 7b (klhdc7b) variants and uses thereof
WO2021255464A1 (en) * 2020-06-17 2021-12-23 Norman Hahn Nutraceutical composition
CN111778340B (zh) * 2020-08-21 2022-08-30 河北医科大学第二医院 一种用于早期***诊断的生物标志物
US20220054578A1 (en) * 2020-08-24 2022-02-24 Life Outside, LLC Composition and method for oral supplement repelling biting insects
CN112322746B (zh) * 2020-09-24 2022-03-18 浙江大学 Snhg9基因在细胞机械应力检测中的应用及试剂盒
CN113057940B (zh) * 2021-03-24 2022-08-19 贵州医科大学 1,8-桉叶油素乳剂及其制备方法
US20230085607A1 (en) * 2021-09-16 2023-03-16 Therapeutic Solutions International, Inc. Ivermectin compositions for treatment of covid-19
CN114225011B (zh) * 2021-12-31 2024-04-12 宁夏医科大学总医院 一种用于预防和治疗gsm的复合制剂及其应用
CN114469909A (zh) * 2022-01-25 2022-05-13 中国医学科学院药用植物研究所 姜黄素在制备治疗arl8a和/或arl8b蛋白高表达肿瘤的药物中的用途
CN114732785A (zh) * 2022-04-14 2022-07-12 辰欣药业股份有限公司 一种大蒜素注射液及其制备方法
WO2024073013A1 (en) * 2022-09-28 2024-04-04 Eresina, Llc Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation
WO2024073699A1 (en) * 2022-09-29 2024-04-04 Muhammed Majeed Compositions for the management of hirsutism
US12011420B2 (en) 2022-10-12 2024-06-18 Epitop, Inc. Compositions and methods for treatment of microbial infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0761931A (ja) * 1993-08-25 1995-03-07 Nippon Zeon Co Ltd 癌転移抑制剤
WO2001003668A1 (en) * 1999-07-08 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Pulmonary delivery of liposome-encapsulated cannabinoids
US20020173538A1 (en) * 2000-06-30 2002-11-21 Ming-Shi Shiao Method for sensitizing cancer cells to cancer therapies with a mevalonate-reducing compound
US6534540B2 (en) * 2000-10-06 2003-03-18 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
CA2511385A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
JP2004217610A (ja) * 2003-01-15 2004-08-05 Internatl Scient:Kk 重水素減少水（スーパーライトウォーター）の生理食塩水による癌、糖尿病、白血病、不眠症の治療および若返り、細胞の活性化、免疫細胞の増加の促進
JP2007022978A (ja) * 2005-07-20 2007-02-01 Hiroshi Nojima がん自然転移抑制剤
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
WO2010084488A1 (en) * 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
AU2010319555A1 (en) * 2009-11-11 2012-06-14 Sanford-Burnham Medical Research Institute Method for generation and regulation of iPS cells and compositions thereof
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
EP2582289B1 (en) * 2010-06-15 2016-09-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) Pdms-based stretchable multi-electrode and chemotrode array for epidural and subdural neuronal recording, electrical stimulation and drug delivery
WO2013134558A1 (en) * 2012-03-07 2013-09-12 The Texas A & M University System Cancer treatment targeting non-coding rna overexpression
CN102908344A (zh) * 2012-08-24 2013-02-06 海口市制药厂有限公司 一种含美罗培南的药物组合物及其制备方法和用途
US9314433B2 (en) * 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
EP2983464A1 (en) * 2013-04-08 2016-02-17 Sederma Production method of meristematic cells of plantago lanceolata, composition comprising said cells or their cellular extract, and cosmetic, nutraceutical and dermatological uses
CN109423517B (zh) * 2017-08-28 2022-08-05 中国医学科学院肿瘤医院 外泌体在肿瘤诊断、治疗和预后评估中的用途

Also Published As

Publication number Publication date
IL261884B (en) 2021-02-28
IL261884A (en) 2018-10-31
WO2017161387A1 (en) 2017-09-21
ZA201806128B (en) 2020-02-26
US20190224193A1 (en) 2019-07-25
BR112018068986B1 (pt) 2023-03-21
MX2018011348A (es) 2019-07-12

Similar Documents

Publication Publication Date Title
BR112018068986A2 (pt) composição para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, método para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, e método para produzir células ips
CR20180503A (es) Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos
BR112018015824A2 (pt) composições para higiene pessoal
AR105600A1 (es) Anticuerpos contra la angiopoyetina implicada en metabolismo de los triglicéridos (anti-angptl8) y usos de los mismos
BR112014029769A2 (pt) composição contendo n-metil-n-acilglucamina
BR112014017650A2 (pt) composições e uso de ésteres de forbol
BR112018006961A2 (pt) composição de fortalecimento para cabelos e método para fortalecer os cabelos
BR112015030918A2 (pt) método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais
BR112015017069A2 (pt) processo para preparação de extrato a partir de meio de cultura de ceriporialacerata e composições farmacêuticas preparadas pelo que para prevenção ou tratamento de doenças diabéticas e complicações diabéticas, que contêm extrato de meio de cultura de ceriporialacerata como ingrediente ativo
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112015028457A2 (pt) Composições cosméticas compreendendo óleo de microalgas
BR112014029762A2 (pt) composição contendo n-metil-n-acilglucamina
BR112017012927A2 (pt) partícula compósita, processo cosmético e métodos para a preparação de uma partícula compósita
BR112017014049A2 (pt) método para reduzir a perda de circulação em uma formação subterrânea, fluido de tratamento e sistema para obstrução de uma zona de perda de circulação
BR112018067597A2 (pt) célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit
BR112019008230A2 (pt) compostos de polímero de liberação de sulfeto de hidrogênio
BR112015005653A2 (pt) Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada
BR112018007384A2 (pt) redução da sensação pungente na pele
BR112017012932A2 (pt) emulsão, processo de preparação de emulsão, uso das partículas compostas e processo de tratamento cosmético de material queratínico
BR112014029885A8 (pt) Composições tópicas, que contêm um retinoide, de tipo emulsão óleo em água
BR112014017162A8 (pt) modulação de biologia vegetal
BR112016028639A2 (pt) composição de tintura de cabelo
BR112014026568A2 (pt) método e aparelho para projeto de componentes de oleoduto
BR112017010453A2 (pt) composição adesiva com mudança de cor
BR112022009836A2 (pt) Método para fornecer células imunes com função aumentada

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2017, OBSERVADAS AS CONDICOES LEGAIS